Swiss regulator approves Roche-Regeneron Covid-19 drug
Monoclonal treatment
Sun Sentinel 2021
The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed by Roche and Regeneron for use in the treatment and prevention of Covid-19.
Ronapreve, a combination of two monoclonal antibodies (casirivimab and imdevimab), is approved for patients 12 years and up when “oxygen therapy or hospitalisation is not required and there is a high risk of developing a severe form of Covid-19,” Swissmedic said in a statementExternal link.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
The treatment can also be taken prophylactically when the immune response to Covid-19 vaccination is not adequate. It is the first drug authorised by the Swiss regulator for the prevention of Covid-19 in cases where there is not a sufficient immune response after vaccination due to other diseases or treatments.
Ronapreve is given as a single infusion into a vein or by injection under the skin. The application for the authorisation of the drug, submitted on March 5, didn’t include data on the efficacy of the drug against the Omicron variant.
Since-April, Ronapreve could be administered under the exceptions allowed in the Covid-19 Ordinance 3; an ordinance published by the Federal Council in June 2020 to combat the pandemic. This includes a list of products that can be placed on the market before the authorisation procedure is concluded.
The antibody cocktail has been authorised in several other locations including in Japan and the European Union. It has a conditional approval in the UK and Australia and is available for emergency use in the United States.
More orders
The Federal Office of Public Health (FOPH) has been building up its Covid-19 treatment reserves. On Monday, the FOPH announced that it had signed two additional contracts for more doses of both Ronapreve (4,000 doses) and the monoclonal drug sotrovimab (2,000 doses) developed by GlaxoSmithKline and Vir Biotechnology. The antibody for the latter was discovered by Swiss company Humabs BioMed.
This is on top of the 3,000 doses of each drug the government ordered earlier this year. Contract amounts are confidential for both drugs, according to the FOPH.
Train vs plane: would you take a direct train between London and Geneva?
Eurostar is planning to run direct trains from Britain to Germany and Switzerland from the early 2030s. Would you favour the train over the plane? If not, why not?
Zurich arbitration authority rules in favour of tenants of ‘Sugus Houses’
This content was published on
A conciliation authority says the terminations of 105 flat leases in the so-called "Sugus Houses" in the centre of Zurich were abusive. The tenants therefore do not have to move out - at least for the time being.
This content was published on
Visitors to Switzerland spent CHF19.6 billion ($23.9 billion) last year, a 2.2% rise compared to the previous year, the Federal Statistical Office (FSO) said on Monday.
This content was published on
Despite the current tense economic situation, Swiss consumer sentiment remains positive. The Swiss spent more money in May than the previous year, particularly on restaurant visits and leisure activities, as shown by the latest figures released by PostFinance.
This content was published on
A bear killed four sheep in the Lower Engadine region near Scuol, canton Graubünden, last week. This was the first bear attack on local livestock in four years.
This content was published on
Experts believe that economic development in Switzerland will be weaker in 2026 than the forecasts made three months ago. They have also lowered their predictions for the current year.
This content was published on
Fewer people in Switzerland have a religious affiliation and the proportion who practice their religion regularly is steadily declining, a survey finds.
Study: trees have major cooling effect even in extreme heat
This content was published on
Plane trees in cities have an important cooling effect even in extreme heat, according to a new study by the Swiss Federal Institute for Forest, Snow and Landscape Research (WSL).
EPFL launches digitised version of Battle of Murten panorama
This content was published on
To mark the anniversary of the Battle of Murten on 22 June 1476, the Federal Institute of Technology Lausanne (EPFL) has launched a website that offers the public an immersive experience of the huge panorama painting of the historic battle.
77th Swiss Gymnastics Festival praised for ‘positive energy’
This content was published on
The 77th Federal Gymnastics Festival drew to a close on Sunday in Lausanne, after eleven days of popular celebration and sporting performances.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
This content was published on
Swiss biopharma firm Roche has been granted emergency authorisation by US authorities to sell its at-home rapid Covid-19 test starting in January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.